Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Añadir filtros








Intervalo de año
1.
Diabetes & Metabolism Journal ; : 602-609, 2011.
Artículo en Inglés | WPRIM | ID: wpr-191388

RESUMEN

BACKGROUND: Research on the relationship between urinary albumin excretion and serum cystatin C in diabetes is restricted to cross-sectional studies. In this study, we investigated how well serial measurements of serum cystatin C level reflect changes in the urinary albumin excretion rate. METHODS: We enrolled and retrospectively collected data on 1,058 participants with type 2 diabetes who were older than 18 years and who had more than 3 years of follow-up with serial measurements of albuminuria and serum cystatin C at an outpatient clinic. RESULTS: With the use of a linear mixed model, we found that the albuminuria level for each patient over time corresponded with the annual change in serum cystatin C-based estimated glomerular filtration rate (cysC-eGFR) but did not correspond with the creatinine-based eGFR calculated by the modification of diet in renal disease formula (MDRD-eGFR). The discrepancy in the direction of the trend was smaller with cysC-eGFR than with MDRD-eGFR. CONCLUSION: Serum cystatin C level reflects the trend in albuminuria level more accurately than serum creatinine level in Korean type 2 diabetes mellitus patients.


Asunto(s)
Humanos , Albuminuria , Creatinina , Cistatina C , Diabetes Mellitus Tipo 2 , Nefropatías Diabéticas , Dieta , Estudios de Seguimiento , Tasa de Filtración Glomerular , Pacientes Ambulatorios , Estudios Retrospectivos
2.
Korean Journal of Blood Transfusion ; : 253-257, 2009.
Artículo en Coreano | WPRIM | ID: wpr-116845

RESUMEN

Cold agglutinin disease (CAD) is a small group of disorders that is characterized by cold-reactive autoantibodies that bind to erythrocyte carbohydrate antigens, and this causes hemagglutination and complement-mediated hemolysis. Autoimmune hemolytic anemia (AIHA) is an immune disorder that is mediated via auto-antibodies produced by lymphoid B cells against red blood cells. The disorder may be a primary (idiopathic) or secondary disease with an underlying autoimmune disease, a lymphoproliferative disorder or infection. The mainstay of initial treatment is immunosuppression with glucocorticosteroids. For those who do not have satisfactory response to initial glucocorticosteroids or they have a relapse after initially successful treatment, splenectomy or other immunosuppressive agents such as azathioprine, cyclosporine and intravenous immunoglobulin (IVIG) could be the next available options. More recently, rituximab, which is a human-murine chimeric monoclonal antibody specific for the CD20 antigen found on the surface of B lymphocytes, is also available. We report here on the successful use of rituximab for the treatment of a Korean elderly patient with CAD and the patient presented with recurrent AIHA.


Asunto(s)
Anciano , Humanos , Anemia Hemolítica Autoinmune , Anticuerpos Monoclonales de Origen Murino , Antígenos CD20 , Autoanticuerpos , Enfermedades Autoinmunes , Azatioprina , Linfocitos B , Frío , Ciclosporina , Eritrocitos , Hemaglutinación , Hemólisis , Enfermedades del Sistema Inmune , Inmunoglobulinas , Terapia de Inmunosupresión , Inmunosupresores , Trastornos Linfoproliferativos , Neumonía Bacteriana , Recurrencia , Esplenectomía , Rituximab
3.
Yonsei Medical Journal ; : 1036-1040, 2008.
Artículo en Inglés | WPRIM | ID: wpr-126732

RESUMEN

Epithelioid hemangioendothelioma (EHE) is a rare tumor of vascular origin. While it can be found in any tissue, it is most often found in lung and liver and usually has an intermediate behavior. EHEs originating from pleural tissue have been less frequently described than those from other sites. Furthermore, to date, all of the cited pleural EHEs were described as highly aggressive. In the present report, we describe a rare case of pleural EHE extending to lung and bone in a 31-year-old woman. The histological diagnosis was confirmed by both conventional examination and immunohistochemistry. Her disease stabilized during the 4th course of adriamycin (45mg/m2, day 1-3), dacarbazine (300mg/m2, day 1-3) and ifosfamide (2,500mg/m2, day 1-3) with mesna, and she survived for 10 months after the diagnosis.


Asunto(s)
Adulto , Femenino , Humanos , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Diagnóstico Diferencial , Factor VIII/metabolismo , Hemangioendotelioma Epitelioide/diagnóstico , Inmunohistoquímica , Queratinas/metabolismo , Neoplasias Pulmonares/diagnóstico , Neoplasias Pleurales/diagnóstico , Vimentina/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA